Dawaa Reference

Clinical reference

Abnormal antenatal screening finding

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources3 sources

ICPC-3 (WONCA International Classification of Primary Care, 3rd edition) class WS50 - condition scope only, no dose · Initial Antepartum Care - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK539829/ · No dose - referral pathway, no medicine given in primary care

Verified against2 documents
  • No dose - referral pathway, no medicine given in primary care
  • Antenatal Fetal Surveillance - disease-level clinical article (abnormal-antenatal-screening-finding-full.txt)

Verified date2026-08

Presentation reference

Is it this?

Reference only, to read alongside your own examination.

Symptoms — what the patient reports (1)

  • Reduced fetal movements - a mother reporting the baby is moving less overall - predicts trouble better than any kick count [reduced fetal movements]

Signs — what you find (2)

  • Isolated variable dips under 30 seconds that do not repeat are not linked to fetal compromise
  • Three variable dips inside 20 minutes is a nonreassuring pattern

Tests (6)

  • A reactive trace means two accelerations, each 15 bpm or more above baseline and held 15 seconds
  • Between 24 and 32 weeks the bar drops to 10 beats above baseline
  • Biophysical profile of 8 or 10 is reassuring and 6 is equivocal
  • Low liquor on its own needs looking into whatever the score, including for ruptured membranes
  • A modified profile is normal only if the trace is reactive and the deepest pool is over 2 cm
  • Absent or reversed end-diastolic flow on umbilical Doppler carries high perinatal mortality

If not this — what else fits (3)

  • Drugs that depress the baby - opioids, phenobarbital, magnesium sulfate, propranolol - flatten reactivity
  • Smoking lowers the accelerations too
  • Prematurity alone: half of traces at 24 weeks and 15 percent at 28 to 32 weeks are nonreactive

SourceStatPearls "Antenatal Fetal Surveillance" - disease-level clinical article

Presentation findings are traced to the source above.

1

NO DRUG THERAPY IN PRIMARY CARE (REFERRAL & ADVICE)

1st line
Adult dose and duration

An abnormal antenatal screening finding requires immediate clinical triage based on the specific test affected. For abnormal glucose tolerance, initiate dietary advice and schedule antenatal monitoring; for positive infection screens, arrange targeted confirmatory testing and appropriate prophylaxis; for blood pressure or proteinuria abnormalities, evaluate urgently for preeclampsia. Correlate all abnormal screening results with obstetric ultrasound and refer promptly to an obstetrician. - Refer, with advice

Paediatric dose

Adult-only condition - paediatric section not applicable

Dose source

No dose - referral pathway, no medicine given in primary care

Why

An abnormal antenatal screening finding requires immediate clinical triage based on the specific test affected. For abnormal glucose tolerance, initiate dietary advice and schedule antenatal monitoring; for positive infection screens, arrange targeted confirmatory testing and appropriate prophylaxis; for blood pressure or proteinuria abnormalities, evaluate urgently for preeclampsia. Correlate all abnormal screening results with obstetric ultrasound and refer promptly to an obstetrician.

Cautions
  • RED FLAG - Reduced fetal movement or fetal growth restriction: assess urgently and refer.
  • An abnormal glucose tolerance test, a positive infection screen, or abnormal blood pressure or protein result needs prompt action specific to that finding.
  • No medicine is prescribed for this in primary care - this entry is for recognition and referral. Anything given is decided by the service it is referred to.
  • RED FLAG - Acute events such as evolving placental abruption and cord prolapse require prompt clinical evaluation and urgent delivery, as routine fetal surveillance is not predictive in these settings.

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.